Neurogene Inc. — Director's Dealing 2014

Mar 6, 2014

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AQUINOX PHARMACEUTICALS, INC (AQXP)
CIK: 0001404644
Period of Report: 2014-03-06

Reporting Person: Alam Kamran (CFO, Vice President Finance)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$5.76	2021-08-21	Common Stock (20833)		Direct
Stock Option (Right to Buy)	$5.76	2022-05-29	Common Stock (10416)		Direct
Stock Option (Right to Buy)	$12.67	2023-10-30	Common Stock (23598)		Direct

Footnotes

F1: The option securities subject to this option shall vest and become exercisable at a rate of twenty-five percent of the option securities underlying the options on the one-year anniversary of the vesting commencement date and 1/48th of the option securities underlying the options each monthly anniversary of the vesting commencement date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total option securities underlying the options shall be fully vested on the four-year anniversary of the vesting commencement date. However, if Mr. Alam terminates his employment for good reason within 12 months following a change of control, 100% of the then unvested shares immediately become fully vested.

F2: Each option granted under the issuer's Joint Canadian Stock Option Plan is exercisable for one "option security." Prior to the closing of the issuer's initial public offering, an option security is comprised of one common exchangeable share and one special voting share of Aquinox Pharmaceuticals Inc., a corporation under the Canadian Business Corporations Act. Following the closing of the issuer's initial public offering, an option security will be comprised of one share of the issuer's common stock.